Alexion Pharmaceuticals Inc. Release: Substantial Disease Burden of PNH Demonstrated in Data from International and Asian Patient Registries Presented at European Hematology Association

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced new research evaluating the substantial disease burden of paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare blood disorder, in patients worldwide. The International PNH Registry, involving 580 patients from 99 sites in 14 countries as of May 2010, found that the debilitating symptoms and life-threatening complications of PNH are similar across patient populations around the world. Data from a separate Asian patient registry, which included 286 patients with PNH in South Korea, examined the clinical manifestations of PNH and concluded that thrombosis is a strong predictor of mortality in these patients. The findings of these patient registries support the need for treatment with Soliris® (eculizumab), a first-in-class terminal complement inhibitor, to improve the prognosis and quality of life for patients living with PNH. The data were presented at the 15th Congress of the European Hematology Association held in Barcelona, Spain on June 10-13, 2010.